Who is on Ozempic for Weight Loss? A Comprehensive Look at the Trend

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Nobody is on Ozempic for weight loss in the regulatory sense, because Ozempic has no weight-management indication — anyone taking it primarily to lose weight is using it off-label. Its FDA labeling covers glycemic control in adults with type 2 diabetes mellitus, cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. That said, the underlying question is a real one, and there is now decent national data on who is actually taking medications in this class. It looks different from the cultural narrative.

The Question Contains a Category Error Worth Fixing First

"Ozempic" has become a placeholder for an entire class the way a handful of brand names have done before it. In practice, the people described in the culture as "on Ozempic for weight loss" are a mixture: adults with type 2 diabetes taking the labeled product for its labeled purpose, adults taking a different semaglutide product that does hold a weight-management indication, adults taking a tirzepatide product, and adults using compounded preparations. Those are four distinct situations with different regulatory status, different evidence and different coverage consequences.

The conflation is not harmless. Because prior authorization criteria are written against approved indications rather than against active ingredients, a request framed around the wrong brand gets denied even when a clinically appropriate option exists. Being precise about which product is being discussed is the difference between a coherent conversation with a prescriber and a circular one.

What the National Data Show About Diabetes Populations

The most rigorous recent U.S. figure comes from the National Center for Health Statistics. In NCHS Data Brief No. 537, drawing on the 2024 National Health Interview Survey, 26.5% of adults with diagnosed diabetes reported using GLP-1 injectables — roughly 6.9 million people. That is about one in four, not the near-universal adoption the coverage implies.

The distribution inside that number is informative. Use peaked at 33.3% among adults aged 50 to 64, with 29.7% among those 35 to 49, 25.3% among those 18 to 34, and 20.8% among adults 65 and older. Women and men were statistically indistinguishable, at 27.2% and 25.9%. By race and ethnicity, use was 31.3% among Hispanic adults, 26.5% among Black non-Hispanic adults, 26.2% among White non-Hispanic adults, and 12.1% among Asian non-Hispanic adults — the one group standing clearly apart from the rest.

Body Size Tracks With Use, But Less Steeply Than Expected

The same NCHS analysis broke use down by weight status among adults with diagnosed diabetes: 32.4% among those with obesity, 22.2% among those with overweight, and 16.7% among those at a healthy weight. The gradient runs in the direction you would predict, but the ends are closer together than the popular framing suggests.

That one in six adults with diabetes at a healthy weight is using a GLP-1 injectable is a useful corrective. These are medications with glycemic, cardiovascular and renal indications, and a substantial share of real-world use has nothing to do with body size at all. Family income showed no statistically significant differences across poverty-level categories in the survey, which cuts against the assumption that this is purely a high-income phenomenon.

What Population Surveys Say About Everyone Else

Broader population data are thinner and less precise, because they rely on self-report across products. A survey fielded in April and May 2025 to a nationally representative sample of 8,793 U.S. adults through the RAND American Life Panel, published in Rand Health Quarterly, found that 11.8% of U.S. adults reported ever having used a GLP-1 agonist, 14.0% expressed interest in using one, and 74.2% reported no plans to use one.

The demographic pattern echoes the diabetes data. Use was highest among women aged 50 to 64, at 20.0%, with 18.5% across all adults aged 50 to 64, 13.1% among adults 65 and older, 11.2% among adults 30 to 49, and 3.3% among adults 18 to 29. The picture that emerges is middle-aged rather than young, and considerably more ordinary than the celebrity-driven version of the story.

Off-Label Prescribing Is Lawful, But It Is Not Approval

A licensed clinician may prescribe an approved medication outside its labeled indication when they judge it clinically appropriate. That practice is legal, longstanding and common across medicine. It does not change a product's approval status, it does not obligate an insurer to cover it, and it does not mean the FDA has reviewed evidence supporting that particular use.

It also concentrates responsibility. When a prescription sits outside the label, the prescriber is not relying on an agency's benefit-risk determination for that population — they are making their own, with your diagnoses, other medications and risk factors in front of them. That is a reason to want a real clinical relationship rather than a transactional one, whatever the medication.

Who Should Not Be Taking Any of Them

Semaglutide products carry a boxed warning stating that semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures, and that it is unknown whether the same occurs in humans. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.

Those exclusions are absolute and are unrelated to how much anyone weighs or how motivated they are. A prescriber screening for them is not creating friction; they are applying the contraindications printed on the label, and the screening is the point of the consultation rather than an obstacle to it.

What the Trend Data Cannot Tell You

Prevalence surveys measure who is taking something, not whether they should be or whether it worked. One thing the real-world literature does consistently show is that staying on treatment is harder than starting it. A narrative review published in Nutrients in 2026 synthesized international real-world evidence and reported persistence ranging from roughly 75% to 80% at twelve months in reimbursed type 2 diabetes cohorts down to below 10% in obesity-focused or high out-of-pocket-cost settings, identifying gastrointestinal intolerance and cost as the primary drivers.

That gap between trial efficacy and real-world persistence is the most underreported part of this story. Whether a medication in this class is appropriate for any individual is a clinical determination made by a licensed prescriber who has evaluated them — not something that can be inferred from a trend line, however large the numbers behind it.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Who is actually taking Ozempic for weight loss?

Anyone taking Ozempic primarily to lose weight is using it off-label, because its FDA labeling covers glycemic control in adults with type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. The brand name has become a placeholder for a whole class, so people described as being "on Ozempic" are often taking a different product entirely.

How many Americans are using GLP-1 medications?

A 2025 survey of 8,793 U.S. adults through the RAND American Life Panel found that 11.8% reported ever using a GLP-1 agonist, 14.0% were interested in using one, and 74.2% had no plans to. Separately, NCHS Data Brief No. 537, based on the 2024 National Health Interview Survey, found that 26.5% of adults with diagnosed diabetes used GLP-1 injectables, or roughly 6.9 million people.

What demographic uses these medications most?

The pattern is middle-aged rather than young. In the RAND survey, use was highest among women aged 50 to 64 at 20.0%, with 18.5% across all adults aged 50 to 64, 13.1% among adults 65 and older, 11.2% among adults 30 to 49, and 3.3% among adults 18 to 29. Among adults with diagnosed diabetes, NCHS found use peaked at 33.3% in the 50 to 64 age group.

Are all GLP-1 users trying to lose weight?

No. Among adults with diagnosed diabetes, NCHS reported GLP-1 injectable use at 32.4% for those with obesity, 22.2% for those with overweight, and 16.7% for those at a healthy weight. That last figure — about one in six — reflects use driven by glycemic, cardiovascular or renal indications rather than by body size. The gradient runs as expected, but the ends are closer together than popular coverage implies.

Do most people stay on these medications?

Often not. A 2026 narrative review in Nutrients synthesizing international real-world evidence reported persistence of roughly 75% to 80% at twelve months in reimbursed type 2 diabetes cohorts, falling below 10% in obesity-focused or high out-of-pocket-cost settings, with several cohorts below 15% by twenty-four months. The primary drivers identified were gastrointestinal intolerance and economic barriers rather than lack of effect.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.